Castle Biosciences (CSTL) Non-Current Deferred Tax Liability (2021 - 2026)

Castle Biosciences has reported Non-Current Deferred Tax Liability for 7 years, with the latest figure at $2.3 million in Q2 2026.

• Quarterly Non-Current Deferred Tax Liability fell 25.72% year-over-year to $2.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.3 million (down 25.72% YoY) and the FY2025 annual result came in at $2.3 million, down 90.39% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $2.3 million in Q2 2026 per CSTL's latest filing, from $2.3 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $27.1 million in Q4 2022 and troughed at $206000.0 in Q1 2024.
• A 5-year average of $5.8 million and a median of $2.3 million in 2026 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability soared 856.92% in 2024, then plunged 90.39% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $27.1 million in 2022, then retreated by 9.0% to $24.7 million in 2023, then fell by 1.58% to $24.3 million in 2024, then slumped by 90.39% to $2.3 million in 2025, then declined by 0.56% to $2.3 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.3 million, $2.3 million, and $2.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.